Back to search results

Understanding Ganciclovir-Resistant CMV Infection in Transplant Patients

This study, called ReCySOHT, is looking at cytomegalovirus (CMV) infections that are resistant or hard to treat with ganciclovir (GCV-RR CMV). This is a problem for people who have received a solid organ transplant (SOT) or a hematopoietic stem cell transplant (HSCT). Researchers want to understand how often these infections happen and what factors might increase your risk of getting one. The goal is to gather information to help prevent and better manage GCV-RR CMV infections in the future. This is an observational study, meaning researchers will collect information from existing medical records. They plan to include about 100 adult patients (18 years or older) who have had a transplant and developed a CMV infection treated with ganciclovir or valganciclovir.

Study design
This is an observational study, meaning researchers will collect information from existing medical records. It aims to include 100 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05234723

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Recruiting
Not specifiedAges 18+Observational
IRCCS Azienda Ospedaliero-Universitaria di Bologna
~100 participants
Updated 2026-06-15 on ClinicalTrials.gov

At a glance

Recruiting sites
7 of 23 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To define incidence of GCV-RR CMV-infection in SOT and HSCT patients
Measured over Through study completion, an average of 1 year
+1 more outcome measured

Conditions

Cytomegalovirus Infections

Explore related trials

Cytomegaloviral InfectionHematopoietic Cell TransplantationSolid organ transplant to recipient

NCT05234723

Where you'd take part

This study runs at 23 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AOU Città della salute e della scienza

    Torino, Italystudy coordinator listed

    Recruiting

  • ASST dei Sette Laghi

    Varese, Italystudy coordinator listed

    Not yet recruiting

  • Azienda Ospedale-Università Padova

    Padova, Italystudy coordinator listed

    Not yet recruiting

  • Azienda Ospedaliera dei Colli

    Naples, Italystudy coordinator listed

    Not yet recruiting

  • Azienda Ospedaliero-Universitaria di Modena

    Modena, Italystudy coordinator listed

    Recruiting

  • Centre Hospitalier Universitaire de Limoges

    Limoges, Limoges, Francestudy coordinator listed

    Not yet recruiting

  • Centre hospitalier universitaire vaudois (CHUV)

    Lausanne, Lausanne, Switzerlandstudy coordinator listed

    Not yet recruiting

  • Gregorio Marañón General University Hospital

    Madrid, Spainstudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Renato Pascale, MD · PRINCIPAL_INVESTIGATOR · IRCCS AOUBO

Who to contact

Renato Pascale, MD
[email protected]
+390512144350
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC
Ability to understand the purpose of the study and provide signed and dated informed consent

Exclusion

Lack of clinical and/or laboratory data regarding the type of CMV event
Lack of the serological mismatch at transplantation
Lack of the type of SOT or HSCT
Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis

What this trial measures

  • To define incidence of GCV-RR CMV-infection in SOT and HSCT patientsThrough study completion, an average of 1 year

    To define incidence of GCV-RR CMV-infection in SOT and HSCT patients

  • To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patientsThrough study completion, an average of 1 year

    To define the risk factors for GCV-RR CMV-infection development in SOT and HSCT patients